First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes.
Van Rampelbergh J, Achenbach P, Leslie RD, Ali MA, Dayan C, Keymeulen B, Owen KR, Kindermans M, Parmentier F, Carlier V, Ahangarani RR, Gebruers E, Bovy N, Vanderelst L, Van Mechelen M, Vandepapelière P, Boitard C.
Van Rampelbergh J, et al. Among authors: vanderelst l.
BMC Med. 2023 May 24;21(1):190. doi: 10.1186/s12916-023-02900-z.
BMC Med. 2023.
PMID: 37226224
Free PMC article.
Clinical Trial.